Innovative deal b/w #FuturaMedical & Atlantis Group for topical #erectiledysfunction gel #MED3000. Joint collab for major China/SE Asia markets (50:50 profit split) & £2m investment. For more on $FUM, the deal, market opportunity, & upcoming catalysts see: https://www.trinitydelta.org/companies/futura-medical/

FY20 saw @NexstimOyj deliver financially & operationally on its 2020-24 strategy. A key goal is exploring accelerated therapy protocols with the @SmartfocusTMS platform: promising 1st pilot data in #depression will guide next steps. $NXTHM / $NXTHS https://www.trinitydelta.org/companies/nexstim/

#AllergyTherapeutics delivers record interim rev, pre-R&D op profit & cash w/ solid recurring sales from its Europe commercial business. 2021 catalysts incl data/clinical progress for Grass (Ph III) & peanut (pre-IND) allergy vaccines. More on $AGY here: https://www.trinitydelta.org/companies/allergy-therapeutics/

2021 shld bring further rev growth, new deals, increased partner pipeline visibility, & more recognition of @MaxCyte_info's role in enabling next-gen #CellTherapy, plus a @NASDAQ IPO.
For our latest $MXCT.L Update see: https://www.trinitydelta.org/company-pages/

Sizeable £40m investment by US specialists gives @MaxCyte_info ample resources to support its clients & partners, & further external recognition of the role of ExPERT in enabling diverse next-generation #CellTherapy #GeneTherapy. For more on $MXCT see: https://www.trinitydelta.org/company-pages/

H121 report highlights a balance sheet transformation in 2020, giving @scancellpharma the funds to progress its 3 promising tech platforms thru early clinical phases & developing follow-on assets. #ImmunoBody #Moditope #Avidimab
For more on $SCLP see: https://www.trinitydelta.org/companies/scancell/